By Josh Beckerman
Shuttle Pharmaceuticals Holdings shares surged after an update related to its Phase 2 clinical trial of ropidoxuridine, a radiation sensitizer for use in combination with radiation therapy to treat brain tumors.
The stock rose 63%, to $2.17, in after-hours trading Monday. As of the market close, shares were down about 63% for the year.
The company said it finalized agreements with all six planned site enrollment locations. Agreements were finalized with Georgetown University Medical Center and UNC Medical Center. It previously reported agreements with four other locations.
Shuttle said in early September that the Phase 2 trial had started enrolling patients with aggressive, IDH wild-type, methylation negative glioblastomas, the company said.
Earlier Monday, Shuttle said Chief Executive Anatoly Dritschilo would present at a ThinkEquity conference Wednesday morning. He will discuss the ropidoxuridine study and provide an update on plans for the Shuttle Diagnostics subsidiary to develop predictive biomarkers for prostate-cancer outcomes following radiation therapy, and novel PSMA ligand for theranostic applications.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 28, 2024 18:50 ET (22:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。